TY - JOUR
T1 - Accelerated therapeutic progress in diffuse large B cell lymphoma
AU - Cai, Qingqing
AU - Westin, Jason
AU - Fu, Kai
AU - Desai, Madhav
AU - Zhang, Liang
AU - Huang, Huiqiang
AU - Jiang, Wenqi
AU - Liang, Rong
AU - Qian, Zhengzi
AU - Champlin, Richard E.
AU - Wang, Michael
N1 - Funding Information:
Acknowledgments This manuscript has been approved by philanthropy funding for Edward E. Crutchfield and Thomas Hunter III. This work was supported by the China Scholarship Council, National Nature Science Foundation of China (81372883, 81001052), Science and Technology Planning Project of Guangdong Province, China (2011B031800222), Young Talents Project of Sun Yat-sen University Cancer Center (to Cai Qingqing), Young Talents Project of Sun Yat-sen University (to Cai Qingqing).
PY - 2014/4
Y1 - 2014/4
N2 - Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma in the world. Clinically, biologically, and pathologically, DLBCL is a heterogeneous entity with a range of potential outcomes. Immunochemotherapy regimens, consisting of the chimeric monoclonal anti-CD20 antibody rituximab in combination with chemotherapy, have improved the outcomes. Relapsed DLBCL is generally treated with salvage immunochemotherapy followed by high-dose therapy and autologous stem cell transplantation; however, DLBCL is not yet curable in up to a third of patients. The real promise for cure lies in novel agents and their rational combinations. The improved understanding of DLBCL subtypes and gene expression profiling has led to the identification of targeted drugs that may allow for subtype specific therapy. We have summarized the existing data on the prognostic factors and the treatment of DLBCL, including the use of novel agents such as lenalidomide, carfilzomib, and ibrutinib. We also share our thoughts on the direction of future clinical trials.
AB - Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma in the world. Clinically, biologically, and pathologically, DLBCL is a heterogeneous entity with a range of potential outcomes. Immunochemotherapy regimens, consisting of the chimeric monoclonal anti-CD20 antibody rituximab in combination with chemotherapy, have improved the outcomes. Relapsed DLBCL is generally treated with salvage immunochemotherapy followed by high-dose therapy and autologous stem cell transplantation; however, DLBCL is not yet curable in up to a third of patients. The real promise for cure lies in novel agents and their rational combinations. The improved understanding of DLBCL subtypes and gene expression profiling has led to the identification of targeted drugs that may allow for subtype specific therapy. We have summarized the existing data on the prognostic factors and the treatment of DLBCL, including the use of novel agents such as lenalidomide, carfilzomib, and ibrutinib. We also share our thoughts on the direction of future clinical trials.
KW - Diffuse large B cell lymphoma
KW - Immunochemotherapy
KW - Novel biological agents
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=84896403797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896403797&partnerID=8YFLogxK
U2 - 10.1007/s00277-013-1979-7
DO - 10.1007/s00277-013-1979-7
M3 - Review article
C2 - 24375125
AN - SCOPUS:84896403797
SN - 0939-5555
VL - 93
SP - 541
EP - 556
JO - Annals of Hematology
JF - Annals of Hematology
IS - 4
ER -